No increased ophthalmic risk with roxadustat treatment in DD CKD-related anaemia
28 Jun 2020
byRoshini Claire Anthony
Roxadustat treatment for anaemia in patients with dialysis-dependent chronic kidney disease (DD CKD) does not come with an increased risk of ophthalmic abnormalities, according to a phase III trial conducted in Japan.
No increased ophthalmic risk with roxadustat treatment in DD CKD-related anaemia
28 Jun 2020
